Sullivan & Cromwell and Ropes & Gray advised on Agilent Technologies’ $950 million acquisition of Biocare Medical.
Agilent Technologies, a global leader in analytical and clinical laboratory technologies, has agreed to acquire Biocare Medical in an all-cash transaction valued at $950 million.
The acquisition strengthens Agilent’s immunohistochemistry offering and expands its ability to serve a wide range of pathology laboratories across clinical and research settings.
Biocare Medical is a recognized leader in immunohistochemistry (IHC) and molecular pathology solutions, with more than 300 specialized antibodies and a robust R&D capability.
Sullivan & Cromwell advised Agilent Technologies. The deal team was led by Pete Jones and Greg Travers.
Ropes & Gray advised Biocare Medical on the transaction.
The team included Private Equity Partners Tim Castelli and Andrew Pomranke, Litigation & Enforcement Partners Zak Goodwin and Ruchit Patel, Tax Partner Elaine Murphy, Employment. Partner Jen Cormier, and Private Equity Counsel Raxit Shah.
